Acorda Therapeutics

E603025

Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.

All labels observed (1)

Label Occurrences
Acorda Therapeutics canonical 1

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf biopharmaceutical company ⓘ
public company ⓘ
activeIngredient dalfampridine ⓘ
linked to: fampridine
businessModel research, development, and commercialization of CNS therapies ⓘ
collaboratesWith academic research institutions ⓘ
other pharmaceutical companies ⓘ
country United States ⓘ
developedProduct Ampyra ⓘ
linked to: fampridine

Inbrija ⓘ
dalfampridine ⓘ
linked to: fampridine
develops therapies for central nervous system conditions ⓘ
therapies for multiple sclerosis ⓘ
focusesOn Parkinson’s disease ⓘ
central nervous system disorders ⓘ
multiple sclerosis ⓘ
neurological disorders ⓘ
foundedBy Ron Cohen ⓘ
hasFounder Ron Cohen ⓘ
hasHeadquartersIn Ardsley, New York, United States ⓘ
linked to: Ardsley, New York
hasKeyPerson Ron Cohen ⓘ
hasKeyPersonRole Chief Executive Officer ⓘ
hasLanguage English ⓘ
hasTherapeuticArea movement disorders ⓘ
neuroinflammation ⓘ
hasTickerSymbol ACOR ⓘ
hasWebsite https://www.acorda.com ⓘ
indication improvement of walking in patients with multiple sclerosis ⓘ
intermittent treatment of OFF episodes in Parkinson’s disease ⓘ
industry biotechnology ⓘ
pharmaceuticals ⓘ
listedOn NASDAQ ⓘ
operatesIn North America ⓘ
international markets ⓘ
productBrandNameOf Ampyra ⓘ
linked to: fampridine
regulatoryRegion United States Food and Drug Administration jurisdiction ⓘ
regulatoryStatus FDA-approved products ⓘ
researchArea remyelination ⓘ
spinal cord injury ⓘ
stroke recovery ⓘ
routeOfAdministration inhalation ⓘ
specializesIn neurodegenerative diseases ⓘ
neurorehabilitation ⓘ
subjectOf clinical trials in Parkinson’s disease ⓘ
clinical trials in multiple sclerosis ⓘ
targetPatientGroup patients with Parkinson’s disease ⓘ
patients with central nervous system disorders ⓘ
patients with multiple sclerosis ⓘ
therapyType CNS-targeted therapies ⓘ
small-molecule drugs ⓘ

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

fampridine → developedBy → Acorda Therapeutics ⓘ